Symbols / PRME Stock $3.70 -3.65% Prime Medicine, Inc.

Healthcare • Biotechnology • United States • NGM
PRME (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Allan Reine M.D.
Exch · Country NGM · United States
Market Cap 668.28M
Enterprise Value 593.94M
Income -201.14M
Sales 4.63M
FCF (ttm) -85.37M
Book/sh 0.68
Cash/sh 1.00
Employees 146
Insider 10d —
IPO Oct 20, 2022
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -4.64
PEG —
P/S 144.27
P/B 5.42
P/C —
EV/EBITDA -2.96
EV/Sales 128.23
Quick Ratio 4.75
Current Ratio 4.84
Debt/Eq 96.33
LT Debt/Eq —
EPS (ttm) -1.35
EPS next Y -0.80
EPS Growth —
Revenue Growth -61.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-03-03
ROA -40.68%
ROE -146.81%
ROIC —
Gross Margin 0.00%
Oper. Margin -58.00%
Profit Margin 0.00%
Shs Outstand 180.62M
Shs Float 105.20M
Insider Own 23.76%
Instit Own 64.56%
Short Float 21.43%
Short Ratio 13.09
Short Interest 30.24M
52W High 6.94
vs 52W High -46.69%
52W Low 1.11
vs 52W Low 233.33%
Beta 2.67
Impl. Vol. 6.25%
Rel Volume 0.63
Avg Volume 2.54M
Volume 1.59M
Target (mean) $6.92
Tgt Median $6.00
Tgt Low $4.25
Tgt High $11.00
# Analysts 9
Recom Buy
Prev Close $3.84
Price $3.70
Change -3.65%
About

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.92
Mean price target
2. Current target
$3.70
Latest analyst target
3. DCF / Fair value
$-8.51
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.70
Low
$4.25
High
$11.00
Mean
$6.92

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-12 init Oppenheimer — → Outperform $11
2025-12-23 init LifeSci Capital — → Outperform $6
2025-11-11 main Citigroup Neutral → Neutral $4
2025-11-10 main Chardan Capital Buy → Buy $9
2025-08-12 main Citigroup Neutral → Neutral $4
2025-08-08 main Chardan Capital Buy → Buy $10
2025-05-27 down Citigroup Buy → Neutral $2
2025-05-20 main JMP Securities Market Outperform → Market Outperform $6
2025-05-20 down JP Morgan Overweight → Neutral —
2025-05-20 down HC Wainwright & Co. Buy → Neutral —
2025-05-19 main Chardan Capital Buy → Buy $12
2025-03-20 main Chardan Capital Buy → Buy $16
2025-03-19 reit HC Wainwright & Co. Buy → Buy $10
2025-03-04 reit Citizens Capital Markets Market Outperform → Market Outperform $10
2025-03-03 reit HC Wainwright & Co. Buy → Buy $10
2025-03-03 main Chardan Capital Buy → Buy $15
2024-12-10 init JMP Securities — → Market Outperform $10
2024-12-03 reit Guggenheim Buy → Buy $18
2024-10-25 reit HC Wainwright & Co. Buy → Buy $10
2024-08-09 reit HC Wainwright & Co. Buy → Buy $10
News
RSS: Latest PRME news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-08-01 NELSEN ROBERT TAYLOR Director and Beneficial Owner of more than 10% of a Class of Security — 3,030,300 $3.30 $9,999,990
2025-08-01 ARCH VENTURE PARTNERS X LLC Beneficial Owner of more than 10% of a Class of Security — 3,030,300 $3.30 $9,999,990
2025-08-01 GV 2021 GP, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 1,500,000 $3.30 $4,950,000
2025-06-30 LIU DAVID R Beneficial Owner of more than 10% of a Class of Security — 21,000 $2.52 $52,830
2025-06-23 LIU DAVID R Beneficial Owner of more than 10% of a Class of Security — 21,000 $2.16 $45,402
2025-06-16 LIU DAVID R Beneficial Owner of more than 10% of a Class of Security — 21,000 $1.49 $31,196
2025-06-11 LIU DAVID R Beneficial Owner of more than 10% of a Class of Security — 21,000 $1.60 $33,590
2025-05-21 REINE ALLAN Chief Executive Officer — 125,000 $1.18 $147,150
2025-05-21 LEE ANN LOUISE Officer — 100,000 $1.13 $113,000
2025-05-20 BRUDNICK RICHARD Officer — 20,000 $1.19 $23,790
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
4.63
+55.28%
2.98
0.00
0.00
Operating Revenue
4.63
+55.28%
2.98
0.00
0.00
Operating Expense
212.98
+3.67%
205.45
+7.40%
191.29
+64.14%
116.54
Research And Development
160.64
+3.44%
155.29
+4.99%
147.91
+70.54%
86.72
Selling General And Administration
52.35
+4.36%
50.16
+15.61%
43.39
+45.50%
29.82
General And Administrative Expense
52.35
+4.36%
50.16
+15.61%
43.39
+45.50%
29.82
Salaries And Wages
23.03
-13.34%
26.57
+55.59%
17.08
+53.92%
11.09
Other Gand A
29.32
+24.28%
23.59
-10.33%
26.31
+40.51%
18.73
Total Expenses
212.98
+3.67%
205.45
+7.40%
191.29
+64.14%
116.54
Operating Income
-208.35
-2.91%
-202.47
-5.84%
-191.29
-64.14%
-116.54
Total Operating Income As Reported
-208.35
-2.91%
-202.47
+1.14%
-204.79
-75.72%
-116.54
EBITDA
-201.03
-2.39%
-196.34
-5.20%
-186.64
-63.26%
-114.32
Normalized EBITDA
-201.46
-2.86%
-195.85
-14.70%
-170.76
-60.80%
-106.19
Reconciled Depreciation
7.32
+19.47%
6.13
+31.70%
4.65
+109.22%
2.22
EBIT
-208.35
-2.91%
-202.47
-5.84%
-191.29
-64.14%
-116.54
Total Unusual Items
0.43
+189.07%
-0.48
+96.95%
-15.88
-95.40%
-8.13
Total Unusual Items Excluding Goodwill
0.43
+189.07%
-0.48
+96.95%
-15.88
-95.40%
-8.13
Special Income Charges
—
0.00
+100.00%
-13.50
0.00
Other Special Charges
—
—
13.50
—
Net Income
-201.14
-2.69%
-195.88
+1.14%
-198.13
-62.64%
-121.82
Pretax Income
-201.14
-2.69%
-195.88
+1.28%
-198.41
-61.61%
-122.77
Net Non Operating Interest Income Expense
4.15
+17.80%
3.52
+25.29%
2.81
—
Net Interest Income
4.15
+17.80%
3.52
+25.29%
2.81
—
Interest Income Non Operating
4.15
+17.80%
3.52
+25.29%
2.81
—
Interest Income
4.15
+17.80%
3.52
+25.29%
2.81
—
Other Income Expense
3.06
-0.13%
3.06
+130.84%
-9.93
-59.53%
-6.22
Other Non Operating Income Expenses
0.15
+260.98%
0.04
-85.04%
0.27
-85.60%
1.90
Gain On Sale Of Security
0.43
+189.07%
-0.48
+79.64%
-2.38
+70.69%
-8.13
Tax Provision
—
0.00
+100.00%
-0.28
+70.57%
-0.95
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
-79.91%
0.00
Tax Effect Of Unusual Items
0.00
0.00
+100.00%
-0.02
+60.75%
-0.06
Net Income Including Noncontrolling Interests
-201.14
-2.69%
-195.88
+1.14%
-198.13
-62.64%
-121.82
Net Income From Continuing Operation Net Minority Interest
-201.14
-2.69%
-195.88
+1.14%
-198.13
-62.64%
-121.82
Net Income From Continuing And Discontinued Operation
-201.14
-2.69%
-195.88
+1.14%
-198.13
-62.64%
-121.82
Net Income Continuous Operations
-201.14
-2.69%
-195.88
+1.14%
-198.13
-62.64%
-121.82
Normalized Income
-201.57
-3.16%
-195.40
-7.20%
-182.27
-60.24%
-113.75
Net Income Common Stockholders
-201.14
-2.69%
-195.88
+1.14%
-198.13
-39.52%
-142.01
Otherunder Preferred Stock Dividend
—
—
—
0.00
Diluted EPS
-1.35
+18.18%
-1.65
+24.31%
-2.18
+47.97%
-4.19
Basic EPS
-1.35
+18.18%
-1.65
+24.31%
-2.18
+47.97%
-4.19
Basic Average Shares
148.76
+25.43%
118.60
+30.37%
90.97
+168.42%
33.89
Diluted Average Shares
148.76
+25.43%
118.60
+30.37%
90.97
+168.42%
33.89
Diluted NI Availto Com Stockholders
-201.14
-2.69%
-195.88
+1.14%
-198.13
-39.52%
-142.01
Preferred Stock Dividends
—
—
—
20.19
Securities Amortization
-2.48
+29.31%
-3.51
+38.22%
-5.68
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
342.73
+15.20%
297.51
+53.47%
193.85
-46.20%
360.31
Current Assets
181.29
-14.44%
211.89
+48.20%
142.98
-51.80%
296.62
Cash Cash Equivalents And Short Term Investments
177.68
-6.70%
190.44
+56.53%
121.67
-58.61%
293.92
Cash And Cash Equivalents
63.03
-65.46%
182.48
+338.92%
41.57
-77.84%
187.62
Other Short Term Investments
114.65
+1339.22%
7.97
-90.05%
80.09
-24.66%
106.30
Prepaid Assets
2.94
-56.63%
6.78
-64.44%
19.06
+677.52%
2.45
Other Current Assets
0.67
-95.40%
14.67
+550.71%
2.25
+816.26%
0.25
Total Non Current Assets
161.44
+88.55%
85.62
+68.30%
50.88
-20.13%
63.70
Net PPE
146.75
+105.07%
71.56
+95.52%
36.60
-24.62%
48.55
Gross PPE
167.18
+96.32%
85.16
+93.17%
44.08
-14.21%
51.38
Accumulated Depreciation
-20.43
-50.28%
-13.60
-81.68%
-7.48
-164.36%
-2.83
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.99
+53.60%
1.94
+572.66%
0.29
+17.48%
0.25
Construction In Progress
0.36
-89.80%
3.58
-33.77%
5.40
+235.95%
1.61
Other Properties
155.92
+109.29%
74.50
+97.01%
37.81
-22.78%
48.97
Leases
7.91
+54.03%
5.14
+787.05%
0.58
+2.66%
0.56
Other Non Current Assets
14.69
+4.47%
14.06
-1.49%
14.28
-5.73%
15.14
Total Liabilities Net Minority Interest
221.87
+53.69%
144.36
+137.51%
60.78
+38.00%
44.04
Current Liabilities
37.45
-1.35%
37.96
-32.72%
56.42
+111.21%
26.71
Payables And Accrued Expenses
12.45
-26.82%
17.01
-53.07%
36.24
+350.61%
8.04
Payables
8.89
-21.71%
11.35
-41.90%
19.54
+350.99%
4.33
Accounts Payable
8.89
-21.71%
11.35
-41.90%
19.54
+350.99%
4.33
Current Accrued Expenses
3.56
-37.08%
5.66
-66.13%
16.70
+350.16%
3.71
Pensionand Other Post Retirement Benefit Plans Current
7.34
-18.26%
8.98
+8.54%
8.27
+26.67%
6.53
Current Debt And Capital Lease Obligation
8.14
+125.15%
3.61
-61.04%
9.28
-20.68%
11.69
Current Capital Lease Obligation
8.14
+125.15%
3.61
-61.04%
9.28
-20.68%
11.69
Current Deferred Liabilities
7.82
+10.32%
7.09
0.00
—
Current Deferred Revenue
7.82
+10.32%
7.09
0.00
—
Other Current Liabilities
1.70
+33.96%
1.27
-51.80%
2.64
+487.75%
0.45
Total Non Current Liabilities Net Minority Interest
184.42
+73.33%
106.40
+2342.00%
4.36
-74.86%
17.33
Long Term Debt And Capital Lease Obligation
108.29
+191.26%
37.18
+753.34%
4.36
-74.45%
17.05
Long Term Capital Lease Obligation
108.29
+191.26%
37.18
+753.34%
4.36
-74.45%
17.05
Non Current Deferred Liabilities
76.13
+9.98%
69.22
0.00
-100.00%
0.28
Non Current Deferred Revenue
76.13
+9.98%
69.22
0.00
—
Non Current Deferred Taxes Liabilities
—
—
0.00
-100.00%
0.28
Stockholders Equity
120.87
-21.08%
153.15
+15.09%
133.07
-57.92%
316.27
Common Stock Equity
120.87
-21.08%
153.15
+15.09%
133.07
-57.92%
316.27
Capital Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Common Stock
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Preferred Stock
—
—
—
0.00
Share Issued
180.51
+37.63%
131.16
+34.69%
97.38
+0.17%
97.21
Ordinary Shares Number
180.51
+37.63%
131.16
+34.69%
97.38
+0.17%
97.21
Additional Paid In Capital
1,009.14
+20.08%
840.36
+34.58%
624.41
+2.39%
609.85
Retained Earnings
-888.35
-29.27%
-687.21
-39.87%
-491.33
-67.58%
-293.20
Gains Losses Not Affecting Retained Earnings
0.08
+8100.00%
0.00
+106.67%
-0.01
+96.09%
-0.38
Other Equity Adjustments
0.08
+8100.00%
0.00
+106.67%
-0.01
—
Total Equity Gross Minority Interest
120.87
-21.08%
153.15
+15.09%
133.07
-57.92%
316.27
Total Capitalization
120.87
-21.08%
153.15
+15.09%
133.07
-57.92%
316.27
Working Capital
143.84
-17.29%
173.93
+100.95%
86.55
-67.93%
269.90
Invested Capital
120.87
-21.08%
153.15
+15.09%
133.07
-57.92%
316.27
Total Debt
116.43
+185.40%
40.79
+199.23%
13.63
-52.57%
28.75
Capital Lease Obligations
116.43
+185.40%
40.79
+199.23%
13.63
-52.57%
28.75
Net Tangible Assets
120.87
-21.08%
153.15
+15.09%
133.07
-57.92%
316.27
Tangible Book Value
120.87
-21.08%
153.15
+15.09%
133.07
-57.92%
316.27
Preferred Stock Equity
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-162.56
-32.31%
-122.86
+25.72%
-165.41
-25.48%
-131.83
Cash Flow From Continuing Operating Activities
-162.56
-32.31%
-122.86
+25.72%
-165.41
-25.48%
-131.83
Net Income From Continuing Operations
-201.14
-2.69%
-195.88
+1.14%
-198.13
-62.64%
-121.82
Depreciation Amortization Depletion
7.32
+19.47%
6.13
+31.70%
4.65
+109.22%
2.22
Depreciation
7.32
+19.47%
6.13
+31.70%
4.65
+109.22%
2.22
Depreciation And Amortization
7.32
+19.47%
6.13
+31.70%
4.65
+109.22%
2.22
Other Non Cash Items
9.70
-21.51%
12.36
-3.39%
12.79
+30.62%
9.79
Stock Based Compensation
29.27
+12.28%
26.07
+87.40%
13.91
+115.36%
6.46
Deferred Tax
—
0.00
+100.00%
-0.28
+71.06%
-0.96
Deferred Income Tax
—
0.00
+100.00%
-0.28
+71.06%
-0.96
Operating Gains Losses
—
—
0.03
+250.00%
0.01
Unrealized Gain Loss On Investment Securities
-0.43
-189.26%
0.48
-79.68%
2.38
-70.69%
8.13
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.03
+250.00%
0.01
Change In Working Capital
-5.34
-117.18%
31.08
+1074.01%
2.65
+107.48%
-35.40
Change In Prepaid Assets
4.54
+128.66%
-15.86
-67.73%
-9.46
-444.02%
-1.74
Change In Payables And Accrued Expense
-0.16
+99.03%
-16.91
-169.33%
24.40
+204.20%
-23.41
Change In Accrued Expense
-1.16
+90.05%
-11.66
-176.40%
15.26
+158.97%
-25.87
Change In Payable
1.00
+118.95%
-5.26
-157.52%
9.14
+271.85%
2.46
Change In Account Payable
1.00
+118.95%
-5.26
-157.52%
9.14
+271.85%
2.46
Change In Other Working Capital
-4.36
-106.20%
70.31
—
—
Change In Other Current Liabilities
-5.36
+17.01%
-6.46
+47.45%
-12.30
-19.98%
-10.25
Investing Cash Flow
-108.76
-258.88%
68.46
+265.86%
18.71
+139.73%
-47.10
Cash Flow From Continuing Investing Activities
-108.76
-258.88%
68.46
+265.86%
18.71
+139.73%
-47.10
Net PPE Purchase And Sale
-4.53
+37.88%
-7.29
+16.39%
-8.72
+45.80%
-16.09
Purchase Of PPE
-4.53
+37.88%
-7.29
+16.39%
-8.72
+45.80%
-16.09
Capital Expenditure
-4.53
+37.88%
-7.29
+16.39%
-8.72
+45.80%
-16.09
Net Investment Purchase And Sale
-104.23
-239.44%
74.75
+170.79%
27.61
+191.00%
-30.34
Purchase Of Investment
-205.41
-58.68%
-129.45
-23.34%
-104.95
+14.91%
-123.34
Sale Of Investment
101.18
-50.45%
204.20
+54.05%
132.56
+42.53%
93.00
Net Other Investing Changes
—
1.00
+688.24%
-0.17
+74.44%
-0.67
Financing Cash Flow
151.51
-22.65%
195.88
+29804.73%
0.66
-99.64%
181.49
Cash Flow From Continuing Financing Activities
151.51
-22.65%
195.88
+29804.73%
0.66
-99.64%
181.49
Net Common Stock Issuance
138.39
-18.66%
170.14
0.00
-100.00%
185.32
Proceeds From Stock Option Exercised
1.12
-94.32%
19.74
+2913.74%
0.66
+199.09%
0.22
Net Other Financing Charges
12.00
+100.00%
6.00
—
-4.04
Changes In Cash
-119.81
-184.69%
141.47
+196.87%
-146.05
-5780.51%
2.57
Beginning Cash Position
196.54
+256.89%
55.07
-72.62%
201.12
+1.29%
198.54
End Cash Position
76.72
-60.96%
196.54
+256.89%
55.07
-72.62%
201.12
Free Cash Flow
-167.09
-28.38%
-130.16
+25.25%
-174.14
-17.72%
-147.92
Income Tax Paid Supplemental Data
—
—
0.00
-100.00%
0.14
Amortization Of Securities
-1.94
+37.39%
-3.09
+9.21%
-3.41
-1263.20%
-0.25
Common Stock Issuance
138.39
-18.66%
170.14
0.00
-100.00%
185.32
Issuance Of Capital Stock
138.39
-18.66%
170.14
0.00
-100.00%
185.32
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category